Product
Help
Pricing
About
Jobs
Log in
Get started
Concept
Add to collection
FOLFIRINOX
OpenAlex ID:
C2777148230
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011
·
Thierry Conroy
, Françoise Desseigne
, et al.
·
New England Journal of Medicine
·
8,653
PDF
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
2018
·
Thierry Conroy
, Pascal Hammel
, et al.
·
New England Journal of Medicine
·
3,184
PDF
Pancreatic cancer
2016
·
Terumi Kamisawa
, Laura D Wood
, et al.
·
The Lancet
·
2,671
Pancreatic Cancer: A Review
2021
·
Wungki Park
, Akhil Chawla
, et al.
·
JAMA
·
2,273
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
2021
·
Thierry Conroy
, Jean-François Bosset
, et al.
·
The Lancet Oncology
·
1,514
PDF
Gemcitabine Plus nab -Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
2011
·
Daniel D. Von Hoff
, Ramesh K. Ramanathan
, et al.
·
Journal of Clinical Oncology
·
1,132
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
2016
·
Mustafa Suker
, Berend R Beumer
, et al.
·
The Lancet Oncology
·
1,033
Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
2014
·
Cristina R. Ferrone
, Giovanni Marchegiani
, et al.
·
Annals of Surgery
·
905
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
2016
·
Timothy M Nywening
, Andrea Wang-Gillam
, et al.
·
The Lancet Oncology
·
878
A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy
2016
·
Qi Qi
, Liping Zhuang
, et al.
·
Cancer
·
875
PDF
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
2018
·
Kyaw L. Aung
, Sandra E. Fischer
, et al.
·
Clinical Cancer Research
·
678
Chemoresistance in Pancreatic Cancer
2019
·
Siyuan Zeng
, Marina Pöttler
, et al.
·
International Journal of Molecular Sciences
·
670
PDF
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
2015
·
Ignacio Garrido-Laguna
, Manuel Hidalgo
·
Nature Reviews Clinical Oncology
·
621
Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients
2016
·
Thilo Hackert
, Milena Sachsenmaier
, et al.
·
Annals of Surgery
·
586
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
2020
·
Eric Van Cutsem
, Margaret A. Tempero
, et al.
·
Journal of Clinical Oncology
·
583
PDF
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes
2014
·
Manuel Hidalgo
, Stefano Cascinu
, et al.
·
Pancreatology
·
581
PDF
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial
2018
·
Janet E. Murphy
, Jennifer Y. Wo
, et al.
·
JAMA Oncology
·
575
PDF
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial
2019
·
Janet E. Murphy
, Jennifer Y. Wo
, et al.
·
JAMA Oncology
·
558
Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
2012
·
Sophie Gourgou-Bourgade
, Caroline Bascoul-Mollevi
, et al.
·
Journal of Clinical Oncology
·
549
PDF
Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma
2017
·
Timothy M Nywening
, Brian A Belt
, et al.
·
Gut
·
531
Irinotecan: 25 years of cancer treatment
2019
·
Christian Bailly
·
Pharmacological Research
·
494
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101
2016
·
Matthew H. G. Katz
, Qian Shi
, et al.
·
JAMA Surgery
·
472
PDF
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
2019
·
Mark J. Truty
, Michael L. Kendrick
, et al.
·
Annals of Surgery
·
471
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011
·
Vanja Vaccaro
, Isabella Sperduti
, et al.
·
New England Journal of Medicine
·
459
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial
2022
·
Thierry Conroy
, Florence Castan
, et al.
·
JAMA Oncology
·
432
Show more works
View as search
Works count:
4,564
Citation count:
83,140
Year
Topic
Type